

Company Factsheet

February 2026

hikma.

Company description

Hikma is a multinational pharmaceutical company. Listed on the London Stock Exchange, we are a global company with a local presence across North America, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products.

Acting responsibly

At Hikma, we strive to put better health within reach, every day and make a difference to people's lives.

We have a duty to act responsibly: for our people, patients, communities and the planet. We have identified four focus areas where we can drive positive impact.



Strategy

We aim to deliver consistent and profitable growth by putting better health within reach every day, creating high-quality medicines and making them accessible for patients around the world. We do this by focusing on three strategic pillars: Strive for excellence, Diversify and differentiate and People and Responsibility.



Injectables

We supply hospitals across our markets with generic and specialty injectable products supported by our manufacturing facilities in the US, Europe and MENA.



Branded

We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.



Hikma Rx

We supply oral, respiratory and other generic and specialty products to the North American retail market, leveraging our state-of-the-art manufacturing facility in Columbus, Ohio.

Key group financials

(Year end December 2025)

Core revenue
2025: \$3,349m
2024: \$3,156m

Core operating profit
2025: \$741m
2024: \$719m

Core EBITDA
2025: \$853m
2024: \$824m


Core basic EPS
2025: 228c
2024: 224c

DPS
2025: 84c
2024: 80c

Net debt to EBITDA
2025: 1.6x
2024: 1.4x

Core results show the underlying performance of the Group, excluding exceptional items.

% Group core revenue



Company strengths - Group core revenue by business segment



Unique and diversified business model



Injectables **42.5%**
Branded **25.4%**
Hikma Rx **31.0%**
Others 1.2%



Strong market position

#3 generic injectable manufacturer in the US¹
#1 pharmaceutical company in MENA²



Commitment to quality

13 US FDA inspected plants
12 EMA-inspected plants



R&D portfolio and pipeline

825+ Products
300+ Products in our pipeline
84 new product launches globally
Received **99** approvals
Submitted **139** regulatory fillings



16%
ROIC

Return on average invested capital
(Return on average invested capital is calculated as core operating profit after tax divided by the average invested capital (calculated as the average of the opening and closing total equity plus net debt).)

1. IQVIA MAT November 2024, generic injectable volumes by eachees, excluding branded generics and Becton Dickinson

2. Based on internal analysis using data from the following source: IQVIA MIDAS[®] Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: MAT December 2025, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Injectables



Core revenue



Core operating profit



Key focus areas

- Continue to grow our base business through our scale and strength of customer relationships
- Launched 50 products globally, including 26 in the US
- Europe and ROW grew by 23%; MENA by 9% and North America by 5%

Products: Includes anti-infectives, pain management, cardiovascular, oncology

Customers: Includes hospitals, Group Purchasing Organisations, Civica Rx

Capabilities: Includes sterile liquid, powder, lyophilised and cytotoxic products, in a broad range of forms, including vials, ampules, bags and prefilled syringes, manufactured in facilities in the US, Portugal, Germany, Italy and MENA

Branded



Core revenue



Core operating profit



Key focus areas

- We operate in 17 markets across the MENA region
- R&D is focused on key markets and high value therapeutic areas, with an increasing focus on chronic illnesses
- We signed 14 deals in MENA in 2025. Partnerships are a key contributor to this business and we work hard to maintain our partner of choice status with global innovative pharma companies
- Launched 36 products

Products: Broad portfolio of branded generics and in-licensed products – we are the partner of choice in the region

Customers: Pharmacies and hospitals across the region

Capabilities: Manufacturing facilities in seven countries, many of which are both locally approved, and US FDA and EMA-approved. 2,000 sales representatives and support staff across our 17 markets

Hikma Rx



Core revenue



Core operating profit



Key focus areas

- Differentiation – offer broad portfolio of differentiated products, including nasal sprays and respiratory
- Quality and operational efficiencies – world-class FDA-inspected facilities
- Pipeline – focus on adding complex and specialty products through R&D and partnerships

Products: Broad product portfolio encompassing oral solids and liquids and leader in US prescription nasal sprays

Customers: 90% of retail generics bought by three customer consortia

Capabilities: State of the art facility in Columbus Ohio, as well as US FDA-inspected facilities in Saudi Arabia and Jordan

Company information

Chief Executive Officer:
Executive Vice Chairman and Deputy CEO, MENA:
Deputy CEO, North America and Europe:
President, US and Global Head of R&D:

Said Darwazah
Mazen Darwazah
Khalid Nablisi
Hafrun Fridriksdottir

Hikma Pharmaceuticals PLC
1 New Burlington Place
London W1S 2HR

Contacts

See www.hikma.com for contact forms